Back to Search
Start Over
Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
- Source :
- Paediatric Respiratory Reviews; Feb2020, Vol. 33, p35-44, 10p
- Publication Year :
- 2020
-
Abstract
- Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV. [ABSTRACT FROM AUTHOR]
- Subjects :
- RESPIRATORY syncytial virus
DEVELOPED countries
BRONCHOPULMONARY dysplasia
CONGENITAL heart disease
NEUROMUSCULAR diseases
PATIENT selection
IMMUNOCOMPROMISED patients
DOWN syndrome
SYSTEMATIC reviews
ANTIVIRAL agents
EVIDENCE-based medicine
GESTATIONAL age
MEDICAL protocols
CYSTIC fibrosis
RESPIRATORY syncytial virus infections
DISEASE complications
Subjects
Details
- Language :
- English
- ISSN :
- 15260542
- Volume :
- 33
- Database :
- Supplemental Index
- Journal :
- Paediatric Respiratory Reviews
- Publication Type :
- Academic Journal
- Accession number :
- 141735000
- Full Text :
- https://doi.org/10.1016/j.prrv.2018.12.001